Arkolith/Insider Trading/TCON/Form 4

Theuer Charles

President and CEO, DirectorTracon Pharmaceuticals, Inc. (TCON) · full profile →Form 4 · filed Mar 2, 2023
Net Buying
Open-Market Buys
$8K
Open-Market Sells
$0
Net Open-Market Flow
$8K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 1, 2023Buy(P)5K$1.52$7K345K
Feb 28, 2023Buy(P)200$1.52$304340K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-014434) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML